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A B S T R A C T
Prenatal carrier screening has expanded to include a large number of genes offered to all couples
considering pregnancy or with an ongoing pregnancy. Expanded carrier screening refers to identiﬁcation
of carriers of single-gene disorders outside of traditional screening guidelines. Expanded carrier
screening panels include numerous autosomal recessive and X-linked genetic conditions, including those
with a very low carrier frequency, as well as those with mild or incompletely penetrant phenotype.
Therefore, the clinical utility of these panels is still subject of debate. Priority should be given to carrier
screening panels that include a comprehensive set of severe childhood-onset disorders. Psychosocial
support and genetic couseling should be available prior to screening and for the return of positive results.
Systems are needed to reduce the \risk of misinterpreting results. Finally, attention should be paid on the
impact of expanded carrier screening on health care organizations and burden of cost.
© 2018 Elsevier B.V. All rights reserved.
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0301-2115/© 2018 Elsevier B.V. All rights reserved.linked recessive disorders in a not at a priori risk population, based
on the personal and family genetic disease history [1].
Nowadays we count more than 2000 recessive disorders among
autosomal and X-linked [2–5]. Recessive disorders affect at least 25
in 10,000 children and 1 in 100 couples are carriers, with a risk of
25% of having a child affected with an autosomal recessive genetic
condition [1,5,6]. Currently, carrier screening is becoming a
standard practice for individuals with a positive family history
of a recessive disease [7].
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screening can be offered to individuals or couples: preconception
screening before pregnancy, and prenatal during pregnancy.
Although the prenatal screening is at present the one most
performed, the preconceptional screening seems to be a better
alternative to allow the parents conscious reproductive choices [7].
Newborn screening must be distinguished from carrier screening.
The aim of newborn screening is to detect deseases for early
treatment by testing directly the newborn. Carrier screening may
allow the neonates to obtain medical care earlier than newborn
screening. Carrier screening alone, however, without newborn
screening would miss many affected neonates [8].
One of the major discussions about carrier scrrening is to whom
it should be offered. It can be offered to individuals, usually the
woman, or couples, especially when a maternal or paternal
mutation is identiﬁed. Moreover, populations with different risks
for heterozygous carrier frequency can be examined: low risk
populations in which the test can be part of a general screening
program or high risk populations because of positive family history
or being a member of a particular ethnic group [2,7,9,10].
In 2013, the American College of Medical Genetics and Genomics
(ACMG) published a position statement on carrier screening.11 For a
disorder to be included in carrier screening, ACMG set the following
criteria: the at-risk patients and their partners identiﬁed would
consider having a prenatal diagnosis; when adult-onset disorders
are included in the screening panels, patients must provide consent
to screening for these conditions; the causative gene(s), mutations
and mutation frequencies should be known in the population being
testedsothatresidualrisk inthosewhotestnegativecan beassessed;
there must be a strong clinical association between mutation(s) and
the severity of the disorder and compliance with ACMG quality
control and proﬁciency testing. Genetic counseling before testing
should be available and post-test genetic counseling for those with
positive results is recommended. ACMG discourages including as
many disorders as possible, not only because it could be not
approprieted belonging to a criteria, but also because it could be
unpractical for a provider to discuss each clinical condition included
in a multidiseasecarrier screening panel [11]. Other societies such as,
ACOG, the National Society of Genetics Counselors and the Society of
Maternal-Fetal Medicine (SMFM) agree with ACMG criteria and
reccomendations [12].
In 2017, the ACOG’s Committee Opinion, Carrier Screening in the
Age of Genomic Medicine, deﬁned similar criteria and recommen-
dations for clinicians to evaluate predeﬁned commercial expanded
carrier panels and to determine their appropriateness [13].
 Expanded carrier screening is an acceptable strategy for
prepregnancy and prenatal screening
 Counseling should be offered;
 Patients should be counseled regarding residual risk with
negative result;
 The reproductive partner of a woman found to be a carrier for a
speciﬁc condition should be offered screening. If carriers for the
same mutation are identiﬁed before pregnancy, genetic counsel-
ing is encouraged to discuss and maximize reproductive options
(donor gametes, preimplantation genetic diagnosis, prenatal
diagnosis);
 Given the high variability of genetic panels currently on the
market, the disorders selected for inclusion should meet several
of the following consensus-determined criteria: have a carrier
frequency of 1 in 100 or greater, have a well-deﬁned phenotype,
have a detrimental effect on quality of life, cause cognitive or
physical impairment, require surgical or medical intervention, or
have an onset early in life. Additionally, screened conditions
should be able to be diagnosed prenatally and may afford
opportunities for antenatal intervention to improve perinataloutcomes, changes to delivery management to optimize
newborn and infant outcomes, and education of the parents
about special care needs after birth. Carrier screening panels
should not include conditions primarily associated with a
disease of adult onset.
Nowadays, carrier screening has expanded to include a larger
number of genes offered to all couples considering pregnancy or
with an ongoing pregnancy. Beneﬁts of including too many
conditions in expanded panels must be weighed against harms in
order to limit the psychological consequences of anxiety,
stigmatization and confusion, ﬁnancial expense, and clinician
time and optimize the utility of the screening [14–16].
Stevens et al. established more speciﬁc criteria for inclusion of
genetic conditions on expanded panels and analyzed several
commercially available screening panels to evaluate if they are in
line with the committee opinion [14]. On average, 73% of
conditions on expanded carrier screening panels they analyzed
did not match the criteria recommended by ACMG and ACOG.
Terhaar et al. found that with a panel of 218 diseases, the likelihood
of identifying a carrier can be as high as 36% [15].
New generation expanded carrier screening
In the age of genomic medicine, the interest in the carrier
screening is growing as the genetic tests are becoming widely
available and their costs are much more affordable. In the past,
carrier screening has evaluated a relatively small group of
mutations selected based on two main characteristics: high
frequency in speciﬁc populations and severe morbidity and
mortality. Currently, commercial laboratories offer test panels
that screen for four to over 1700 diseases, which are not selected
based on racial or ethnic background. The majority of conditions
are autosomal-recessive, but some may be X-linked or autosomal-
dominant single gene disorders. The rationale for expanded carrier
screening is that the majority of carrier individuals have no family
history of the genetic condition(s) they carry, or are not aware of
their full ancestry or true ethnicity. Table 1 shows one of the
preconceptional expanded carrier screening panels available on
the market, including more than 700 conditions. These expanded
panels include also some conditions that result in only mild to
moderate health complications (e.g. factor V Leiden), have
signiﬁcant variations in or poorly deﬁned pehotype (e.g. fragile
X) or have onset in adulthood (e.g. BRCA1/2). The frequency of
some conditions is unknown in the general population, rendering
calculation of residual risk after a positive test inconclusive.
Including these type of conditions in a screening panel is in direct
conﬂict with the accepted clinical criteria for screening programs
[4,6,12]. Moreover, identifying variants of uncertain clinical
signiﬁcance, may create patient anxiety despite counselling, which
will complex and time-consuming with the inclusion of large set of
disorders on the expanded screening panel. Therefore, the clinical
utility of these exapanded panels is still subject to debate.
Diseases screened
In 1968, Wilson and Jungner outlined the principles for using a
screening test for early disease detection [4]. These principles are
still used by the World Health Organization and are still valid to
justify a screening program. For reproductive screening, the aim is
not of early diagnosis but to facilitate reproductive decision
making.
One of the biggest challenges in the development of expanded
carrier screening is to identify the appropriate criteria to uniform
the test and to reduce the huge variability in current commercially
available panels. The European Society of Human Genetics
Table 1
Example of one of the preconceptional expanded carrier screening panel available on the market.
Disease Name PhenOMIM Gene
1 17-alpha-hydroxylase/17,20-lyase deﬁciency 202110 CYP17A1
2 17-beta-hydroxysteroid dehydrogenase X deﬁciency 300438 HSD17B10
3 3-beta-hydroxysteroid dehydrogenase, type II, deﬁciency 201810 HSD3B2
4 3-hydroxy-3-methylglutaric aciduria 246450 HMGCL
5 3-methylglutaconic aciduria type 1 250950 AUH
6 3-methylglutaconic aciduria type 3 258501 OPA3
7 46XY sex reversal 3 612965 NR5A1
8 4-hydroxybutyric aciduria 271980 ALDH5A1
9 Aarskog-Scott syndrome 305400 FGD1
10 ABCD syndrome 600501 EDNRB
11 Achalasia-addisonianism-alacrimia syndrome 231550 AAAS
12 Achondrogenesis type 1B 600972 SLC26A2
13 Acyl-CoA dehydrogenase 9 deﬁciency 611126 ACAD9
14 Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deﬁciency 202010 CYP11B1
15 Adrenal insufﬁciency, congenital, with 46XY sex reversal, partial or complete 613743 CYP11A1
16 Adrenocortical insufﬁciency 612965 NR5A1
17 Adrenoleukodystrophy 300100 ABCD1
18 Adult neuronal ceroid lipofuscinosis 256730 PPT1
19 Adult neuronal ceroid lipofuscinosis 10 610127 CTSD
20 Adult neuronal ceroid lipofuscinosis 4A 204300 CLN6
21 Aicardi-Goutières syndrome 225750 TREX1
22 Aicardi-Goutieres syndrome 2 610181 RNASEH2B
23 Aicardi-Goutieres syndrome 3 610329 RNASEH2C
24 Aicardi-Goutieres syndrome 4 610333 RNASEH2A
25 Aicardi-Goutieres syndrome 5 612952 SAMHD1
26 Aldosteronism, glucocorticoid-remediable 103900 CYP11B1
27 Allan-Herndon-Dudley syndrome 300523 SLC16A2
28 Alpers syndrome 203700 POLG
29 Alpha-methylacyl-Coa Racemase deﬁciency 614307 AMACR
30 Alph A-T halassemia 604131 HBA1
31 Alph A-T halassemia myelodysplasia syndrome, somatic 300448 ATRX
32 Alph A-T halassemia/mental retardation syndrome 301040 ATRX
33 Alport syndrome 301050 COL4A5
34 Alport syndrome autosomal recessive (gene COL4A3) 203780 COL4A3
35 Alport syndrome autosomal recessive (gene COL4A4) 203780 COL4A4
36 Alström syndrome 203800 ALMS1
37 Amish infantile epilepsy syndrome 609056 ST3GAL5
38 Amyotrophic lateral sclerosis 2, juvenile 205100 ALS2
39 Anauxetic dysplasia 607095 RMRP
40 Angelman syndrome 105830 UBE3A
41 Antenatal Bartter syndrome 241200 KCNJ1
42 Antenatal Bartter syndrome type 1 601678 SLC12A1
43 Antley-Bixler syndrome with genital anomalies and disordered
steroidogenesis
201750 POR
44 Aplasia/hypoplasia of limbs and pelvis 276820 WNT7A
45 Aplastic anemia 609135 NBN
46 Apparent mineralocorticoid excess 218030 HSD11B2
47 Argininosuccinic aciduria 207900 ASL
48 Aromatic L-amino acid decarboxylase deﬁciency 608643 DDC
49 Arthrogryposis - renal dysfunction - cholestasis 208085 VPS33B
50 Arthrogryposis, renal dysfunction, and cholestasis 2 613404 VIPAR
51 Ataxia - oculomotor apraxia type 1 208920 APTX
52 Ataxia with vitamin E deﬁciency 277460 TTPA
53 Ataxi A-T elangiectasia 208900 ATM
54 Atelosteogenesis type II 256050 SLC26A2
55 Autism, susceptibility to, X-linked 5 300847 RPL10
56 Autoimmune lymphoproliferative syndrome, type IA 601859 FAS
57 Autoimmune lymphoproliferative syndrome, type IB 601859 FASLG
58 Autoimmune lymphoproliferative syndrome, type II 603909 CASP10
59 Autoimmune polyendocrinopathy syndrome, type I, with or without
reversible metaphyseal dysplasia
240300 AIRE
60 Autosomal dominant Charcot-Marie-Tooth disease type 2K 607831 GDAP1
61 Autosomal recessive ataxia due to ubiquinone deﬁciency 612016 ADCK3
62 Autosomal recessive Charcot-Marie-Tooth disease with hoarseness 607706 GDAP1
63 Autosomal recessive distal spinal muscular atrophy type 4 611067 PLEKHG5
64 Autosomal recessive dopa-responsive dystonia 605407 TH
65 Autosomal recessive hypophosphatemic rickets 1 241520 DMP1
66 Autosomal recessive hypophosphatemic rickets 2 613312 ENPP1
67 Autosomal recessive intermediate Charcot-Marie-Tooth disease type A 608340 GDAP1
68 Autosomal recessive limb-girdle muscular dystrophy type 2I 607155 FKRP
69 Autosomal recessive limb-girdle muscular dystrophy type 2M 611588 FKTN
70 Autosomal recessive limb-girdle muscular dystrophy type C 613157 POMGNT1
71 Autosomal recessive limb-girdle muscular dystrophy type C 609308 POMT1
72 Autosomal recessive limb-girdle muscular dystrophy type C 613158 POMT2
73 Autosomal recessive malignant osteopetrosis 1 259700 TCIRG1
74 Autosomal recessive malignant osteopetrosis 4 611490 CLCN7
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Table 1 (Continued)
Disease Name PhenOMIM Gene
75 Autosomal recessive nonsyndromic sensorineural deafness type DFNB12 601386 CDH23
76 Autosomal recessive nonsyndromic sensorineural deafness type DFNB18 602092 USH1C
77 Autosomal recessive nonsyndromic sensorineural deafness type DFNB1A (gene GJB2) 220290 GJB2
78 Autosomal recessive nonsyndromic sensorineural deafness type DFNB2 600060 MYO7A
79 Autosomal recessive polycystic kidney disease 263200 PKHD1
80 Autosomal recessive progressive external ophthalmoplegia 258450 POLG
81 Autosomal recessive spastic ataxia of Charlevoix-Saguenay 270550 SACS
82 Autosomal recessive spondylocostal dysostosis 1 277300 DLL3
83 Bannayan-Riley-Ruvalcaba syndrome 153480 PTEN
84 Barth syndrome 302060 TAZ
85 Becker muscular dystrophy 300376 DMD
86 Beckwith-Wiedemann syndrome 130650 NSD1
87 Bet A-T halassemia 613985 HBB
88 Bethlem myopathy 158810 COL6A1
89 Bethlem myopathy 158810 COL6A2
90 Bethlem myopathy 158810 COL6A3
91 Bifunctional enzyme deﬁciency 261515 HSD17B4
92 Biotinidase deﬁciency 253260 BTD
93 Björnstad syndrome 262000 BCS1L
94 Bloom syndrome 210900 BLM
95 Brachytelephalangic chondrodysplasia punctata 302950 ARSE
96 Brittle cornea syndrome 229200 ZNF469
97 Caffey disease 114000 COL1A1
98 Canavan disease 271900 ASPA
99 Carbamoylphosphate synthetase deﬁciency 237300 CPS1
100 Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deﬁciency 1 604377 SCO2
101 Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deﬁciency 2 615119 COX15
102 Carnitine deﬁciency, systemic primary 212140 SLC22A5
103 Carnitine palmitoyl transferase 1A deﬁciency 255120 CPT1A
104 Carnitine palmitoyl transferase II deﬁciency, infantile form 600649 CPT2
105 Carnitine palmitoyl transferase II deﬁciency, neonatal form 608836 CPT2
106 Carnitine-acylcarnitine translocase deﬁciency 212138 SLC25A20
107 Carpenter syndrome 201000 RAB23
108 Cartilage-hair hypoplasia 250250 RMRP
109 Cataract - intellectual deﬁcit - hypogonadism 212720 RAB3GAP2
110 Cataract 40, X-linked 302200 NHS
111 Cerebellar ataxia - intellectual deﬁcit - dysequilibrium syndrome 224050 VLDLR
112 Cerebral dysgenesis-neuropathy-ichthyosis-palmoplantar keratoderma syndrome 609528 SNAP29
113 Cerebrotendinous xanthomatosis 213700 CYP27A1
114 Charcot-Marie-Tooth disease axonal type 2B1 605588 LMNA
115 Charcot-Marie-Tooth disease type 4A 214400 GDAP1
116 Charcot-Marie-Tooth disease type 4E 605253 EGR2
117 Charcot-Marie-Tooth disease type 4F 614895 PRX
118 Charcot-Marie-Tooth disease type 4H 609311 FGD4
119 Charcot-Marie-Tooth disease, type 1A 118220 PMP22
120 Charcot-Marie-Tooth disease, type 1B 118200 MPZ
121 Charcot-Marie-Tooth disease, type 1E 118300 PMP22
122 Charcot-Marie-Tooth disease, type 2I 607677 MPZ
123 Charcot-Marie-Tooth disease, type 2J 607736 MPZ
124 Chediak-Higashi syndrome 214500 LYST
125 Chilblain lupus 2 614415 SAMHD1
126 Childhood-onset hypophosphatasia 241510 ALPL
127 Cholestasis, benign recurrent intrahepatic 243300 ATP8B1
128 Cholestasis, benign recurrent intrahepatic, 2 605479 ABCB11
129 Cholestasis, intrahepatic, of pregnancy, 1 147480 ATP8B1
130 Cholestasis, intrahepatic, of pregnancy, 3 614972 ABCB4
131 Cholestasis, progressive familial intrahepatic 1 211600 ATP8B1
132 Cholestasis, progressive familial intrahepatic 2 601847 ABCB11
133 Cholestasis, progressive familial intrahepatic 3 602347 ABCB4
134 Chondrodysplasia, Blomstrand type 215045 PTH1R
135 Citrullinemia type I 215700 ASS1
136 Classic congenital adrenal hyperplasia due to 21-hydroxylase deﬁciency 201910 CYP21A2
137 Classic galactosemia 230400 GALT
138 Classic maple syrup urine disease 248600 DBT
139 Classical homocystinuria 236200 CBS
140 COACH syndrome 216360 TMEM67
141 Cockayne syndrome type A 216400 ERCC8
142 Cockayne syndrome type B 133540 ERCC6
143 Coenzyme Q10 deﬁciency, primary, 5 614654 COQ9
144 Cofﬁn-Lowry syndrome 303600 RPS6KA3
145 COFS syndrome 1 214150 ERCC6
146 Cohen Syndrome type 1 216550 VPS13B
147 Cold-induced sweating syndrome 272430 CRLF1
148 Combined immunodeﬁciency with skin granulomas 233650 RAG1
149 Combined immunodeﬁciency with skin granulomas 233650 RAG2
150 Combined oxidative phosphorylation defect type 2 610498 MRPS16
151 Combined oxidative phosphorylation defect type 5 611719 MRPS22
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Disease Name PhenOMIM Gene
152 Combined oxidative phosphorylation deﬁciency 4 610678 TUFM
153 Combined pituitary hormone deﬁciencies, genetic forms 182230 HESX1
154 Combined pituitary hormone deﬁciencies, genetic forms 613038 POU1F1
155 Combined pituitary hormone deﬁciencies, genetic forms 262600 PROP1
156 Combined pituitary hormone deﬁciency with spine abnormalities 221750 LHX3
157 Complete androgen insensitivity syndrome 300068 AR
158 Complex I, mitochondrial respiratory chain, deﬁciency of 252010 NDUFS6
159 Congenital bile acid synthesis defect type 4 214950 AMACR
160 Congenital disorder of glycosylation type 1a 212065 PMM2
161 Congenital disorder of glycosylation type 1b 602579 MPI
162 Congenital disorder of glycosylation type 1e 608799 DPM1
163 Congenital disorder of glycosylation type 1j 608093 DPAGT1
164 Congenital disorder of glycosylation type 2a 212066 MGAT2
165 Congenital disorder of glycosylation type 2c 266265 SLC35C1
166 Congenital disorder of glycosylation type 2d 607091 B4GALT1
167 Congenital disorder of glycosylation type 2f 603585 SLC35A1
168 Congenital disorder of glycosylation type Ic 603147 ALG6
169 Congenital disorder of glycosylation type Ik 608540 ALG1
170 Congenital disorder of glycosylation, type Id 601110 ALG3
171 Congenital disorder of glycosylation, type If 609180 MPDU1
172 Congenital disorder of glycosylation, type Ig 607143 ALG12
173 Congenital disorder of glycosylation, type Ih 608104 ALG8
174 Congenital disorder of glycosylation, type Ii 607906 ALG2
175 Congenital disorder of glycosylation, type IIb 606056 MOGS
176 Congenital disorder of glycosylation, type IIe 608779 COG7
177 Congenital disorder of glycosylation, type IIg 611209 COG1
178 Congenital disorder of glycosylation, type IIh 611182 COG8
179 Congenital disorder of glycosylation, type Il 608776 ALG9
180 Congenital disorder of glycosylation, type Im 610768 DOLK
181 Congenital disorder of glycosylation, type In 612015 RFT1
182 Congenital disorder of glycosylation, type Iq 612379 SRD5A3
183 Congenital ﬁbrinogen deﬁciency (gene FGA) 202400 FGA
184 Congenital heart defects, nonsyndromic, 1, X-linked 306955 ZIC3
185 Congenital hereditary endothelial dystrophy type II 217700 SLC4A11
186 Congenital lipoid adrenal hyperplasia 201710 STAR
187 Congenital malabsorptive diarrhea due to paucity of enteroendocrine cells 610370 NEUROG3
188 Congenital muscular dystrophy type 1A 607855 LAMA2
189 Congenital muscular dystrophy type 1D 608840 LARGE
190 Congenital muscular dystrophy type 4B 613152 FKTN
191 Congenital muscular dystrophy type 5B 606612 FKRP
192 Congenital muscular dystrophy with cerebellar involvement 613151 POMGNT1
193 Congenital muscular dystrophy with cerebellar involvement 613155 POMT1
194 Congenital muscular dystrophy with cerebellar involvement 613156 POMT2
195 Corneal dystrophy - perceptive deafness 217400 SLC4A11
196 Corpus callosum agenesis - neuronopathy 218000 SLC12A6
197 Corpus callosum hypoplasia-retardation-adducted thumbs-spasticity- hydrocephalus syndrome 307000 L1CAM
198 Cowden syndrome 1 158350 PTEN
199 Craniofrontonasal dysplasia 304110 EFNB1
200 Cutis laxa, autosomal dominant 2 614434 FBLN5
201 Cutis laxa, autosomal recessive, type IA 219100 FBLN5
202 Cutis laxa, autosomal recessive, type IB 614437 EFEMP2
203 Cutis laxa, autosomal recessive, type IIA 219200 ATP6V0A2
204 Cystic ﬁbrosis; mucoviscidosis 219700 CFTR
205 Cystinosis 219800 CTNS
206 Deafness - encephaloneuropathy - obesity - valvulopathy 614651 PDSS1
207 Dejerine-Sottas disease 145900 MPZ
208 Dejerine-Sottas disease 145900 PMP22
209 Dent disease 300009 CLCN5
210 Dent disease 2 300555 OCRL
211 Desmosterolosis 602398 DHCR24
212 Diabetes mellitus, noninsulin-dependent 125853 ABCC8
213 Diabetes mellitus, permanent neonatal 606176 ABCC8
214 Diabetes mellitus, transient neonatal 2 610374 ABCC8
215 Diastrophic dwarﬁsm 222600 SLC26A2
216 Dihydropyrimidine dehydrogenase deﬁciency 274270 DPYD
217 Dilated cardiomyopathy with ataxia 610198 DNAJC19
218 Donnai-Barrow syndrome 222448 LRP2
219 Duchenne muscular dystrophy 310200 DMD
220 Dyskeratosis congenita X-linked 305000 DKC1
221 Dystrophic epidermolysis bullosa pruriginosa 604129 COL7A1
222 Early infantile epileptic encephalopathy 308350 ARX
223 Early infantile epileptic encephalopathy 609304 SLC25A22
224 Ectodermal dysplasia 1, hypohidrotic, X-linked 305100 EDA
225 Ectodermal dysplasia, hypohidrotic, with immune deﬁciency 300291 IKBKG
226 Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeﬁciency 300301 IKBKG
227 Ehlers-Danlos syndrome type 6 225400 PLOD1
228 Ehlers-Danlos syndrome, cardiac valvular type 225320 COL1A2
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Disease Name PhenOMIM Gene
229 Ehlers-Danlos syndrome, type I 130000 COL1A1
230 Ehlers-Danlos syndrome, type VIIA 130060 COL1A1
231 Eiken syndrome 600002 PTH1R
232 Ellis-van Creveld syndrome 225500 EVC2
233 Ellis-van Creveld syndrome 225500 EVC
234 Encephalopathy due to prosaposin deﬁciency 611721 PSAP
235 Epidermolysis bullosa simplex with muscular dystrophy 226670 PLEC
236 Epidermolysis bullosa simplex with pyloric atresia 612138 PLEC
237 Epilepsy, progressive myoclonic 2A (Lafora) 254780 EPM2A
238 Epilepsy, progressive myoclonic 2B (Lafora) 254780 NHLRC1
239 Epilepsy, pyridoxine-dependent 266100 ALDH7A1
240 Epileptic encephalopathy, early infantile, 15 615006 ST3GAL3
241 Epileptic encephalopathy, early infantile, 2 300672 CDKL5
242 Epileptic encephalopathy, early infantile, 8 300607 ARHGEF9
243 Epileptic encephalopathy, early infantile, 9 300088 PCDH19
244 Escobar syndrome 265000 CHRNG
245 Ethylmalonic encephalopathy 602473 ETHE1
246 Exudative vitreoretinopathy 2, X-linked 305390 NDP
247 Fabry disease 301500 GLA
248 Failure of tooth eruption, primary 125350 PTH1R
249 Familial dysautonomia 223900 IKBKAP
250 Familial hypomagnesemia - hypercalciuria - nephrocalcinosis - severe ocular 248190 CLDN19
involvement
251 Familial Mediterranean fever 249100 MEFV
252 Fanconi anemia complementation group C 227645 FANCC
253 Fatal infantile lactic acidosis with methylmalonic aciduria 245400 SUCLG1
254 Fatal mitochondrial disease due to combined oxidative phosphorylation deﬁciency 3 610505 TSFM
255 Favism 134700 G6PD
256 Fertile eunuch syndrome 228300 GNRHR
257 Fetal akinesia deformation sequence 208150 RAPSN
258 Fetal akinesia deformation sequence 208150 DOK7
259 Fetal Gaucher disease 608013 GBA
260 FG syndrome 4 300422 CASK
261 Fibular hypoplasia or aplasia - femoral bowing - oligodactyly 228930 WNT7A
262 Fraser syndrome (gene FRAS1) 219000 FRAS1
263 Fraser syndrome (gene FRAS2) 219000 FREM2
264 Free sialic acid storage disease, infantile form 269920 SLC17A5
265 French-Canadian type Leigh syndrome 220111 LRPPRC
266 Fucosidosis 230000 FUCA1
267 Fukuyama congenital muscular dystrophy 253800 FKTN
268 Fumaric aciduria 606812 FH
269 Galactokinase deﬁciency with cataracts 230200 GALK1
270 Gallbladder disease 1 600803 ABCB4
271 Gaucher disease type 2 230900 GBA
272 Gaucher disease type 3 231000 GBA
273 Gaucher disease type 3C 231005 GBA
274 Geleophysic dysplasia 1 231050 ADAMTSL2
275 Generalized junctional epidermolysis bullosa, non-Herlitz type 226650 COL17A1
276 Glutaric acidemia type 2 (gene ETFA) 231680 ETFA
277 Glutaric acidemia type 2 (gene ETFB) 231680 ETFB
278 Glutaric acidemia type 2 (gene ETFDH) 231680 ETFDH
279 Glutaryl-CoA dehydrogenase deﬁciency 231670 GCDH
280 Glutathione synthetase deﬁciency with 5-oxoprolinuria 266130 GSS
281 Glycine encephalopathy 605899 AMT
282 Glycine encephalopathy 605899 GCSH
283 Glycine encephalopathy 605899 GLDC
284 Glycogen storage disease due to acid maltase deﬁciency 232300 GAA
285 Glycogen storage disease due to glucose-6-phosphatase deﬁciency type 1a 232200 G6PC
286 Glycogen storage disease due to glucose-6-phosphatase deﬁciency type b 232220 SLC37A4
287 Glycogen storage disease due to glucose-6-phosphatase deﬁciency type c 232240 SLC37A4
288 Glycogen storage disease due to glycogen branching enzyme deﬁciency, childhood combined hepatic and myopathic form 232500 GBE1
289 Glycogen storage disease due to glycogen debranching enzyme deﬁciency 232400 AGL
290 Glycogen storage disease due to muscle glycogen phosphorylase deﬁciency 232600 PYGM
291 GM1 gangliosidosis type 1 230500 GLB1
292 GM1 gangliosidosis type 2 230600 GLB1
293 GM1 gangliosidosis type 3 230650 GLB1
294 GRACILE syndrome 603358 BCS1L
295 Greenberg dysplasia 215140 LBR
296 Griscelli disease type 1 214450 MYO5A
297 Griscelli disease type 2 607624 RAB27A
298 Guanidinoacetate methyltransferase deﬁciency 612736 GAMT
299 Hemochromatosis, type 2A 602390 HFE2
300 Hemolytic anemia due to G6PD deﬁciency 300908 G6PD
301 Hemolytic anemia due to red cell pyruvate kinase deﬁciency 266200 PKLR
302 Hemophagocytic lymphohistiocytosis, familial, 2 603553 PRF1
303 Hemophagocytic lymphohistiocytosis, familial, 3 608898 UNC13D
304 Hemophagocytic lymphohistiocytosis, familial, 4 603552 STX11
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305 Hemophagocytic lymphohistiocytosis, familial, 5 613101 STXBP2
306 Hemophilia A 306700 F8
307 Hemophilia B 306900 F9
308 Hepatic venoocclusive disease with immunodeﬁciency 235550 SP110
309 Hepatoencephalopathy due to combined oxidative phosphorylation deﬁciency type 1 609060 GFM1
310 Hereditary fructose intolerance 229600 ALDOB
311 Hereditary sensory and autonomic neuropathy type 4 256800 NTRK1
312 Hermansky-Pudlak syndrome 2 608233 AP3B1
313 Hermansky-pudlak syndrome 9 614171 PLDN
314 Heterotaxy, visceral, 1, X-linked 306955 ZIC3
315 Histidinemia 235800 HAMP
316 Holocarboxylase synthetase deﬁciency 253270 HLCS
317 Hoyeraal-Hreidarsson syndrome 300240 DKC1
318 Hyaline ﬁbromatosis syndrome 228600 ANTXR2
319 Hyperammonemia due to N-acetylglutamate synthetase deﬁciency 237310 NAGS
320 Hyper-IgE recurrent infection syndrome, autosomal recessive 243700 DOCK8
321 Hyperinsulinemic hypoglycemia, familial, 1 256450 ABCC8
322 Hyperornithinemia-hyperammonemia-homocitrullinuria 238970 SLC25A15
323 Hypoglycemia of infancy, leucine-sensitive 240800 ABCC8
324 Hypogonadotropic hypogonadism 7 without anosmia 146110 GNRHR
325 Hypomyelination - congenital cataract 610532 FAM126A
326 Hypoparathyroidism - intellectual deﬁcit - dysmorphism syndrome 241410 TBCE
327 Hypophosphatemic rickets 300554 CLCN5
328 Ichthyosis follicularis - alopecia - photophobia 308205 MBTPS2
329 Ichthyosis, autosomal recessive 4B (harlequin) 242500 ABCA12
330 Ichthyosis, congenital, autosomal recessive 1 242300 TGM1
331 Ichthyosis, congenital, autosomal recessive 4A 601277 ABCA12
332 Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 607626 CLDN1
333 Immunodeﬁciency 10 612783 STIM1
334 Immunodeﬁciency 17, CD3 gamma deﬁcient 615607 CD3G
335 Immunodeﬁciency 18, SCID variant 615615 CD3E
336 Immunodeﬁciency 19 615617 CD3D
337 Immunodeﬁciency 27A, mycobacteriosis, AR 209950 IFNGR1
338 Immunodeﬁciency 28, mycobacteriosis 614889 IFNGR2
339 Immunodeﬁciency 29, mycobacteriosis 614890 IL12B
340 Immunodeﬁciency 30 614891 IL12RB1
341 Immunodeﬁciency 31A, mycobacteriosis, autosomal dominant 614892 STAT1
342 Immunodeﬁciency 31B, mycobacterial and viral infections, autosomal recessive 613796 STAT1
343 Immunodeﬁciency 31C, autosomal dominant 614162 STAT1
344 Immunodeﬁciency 33 300636 IKBKG
345 Immunodeﬁciency 35 611521 TYK2
346 Immunodeﬁciency 9 612782 ORAI1
347 Immunodeﬁciency, common variable, 1 607594 ICOS
348 Immunodeﬁciency, common variable, 3 613493 CD19
349 Immunodeﬁciency-centromeric instability-facial anomalies syndrome 1 242860 DNMT3B
350 Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked 304790 FOXP3
351 Incontinentia pigmenti, type II 308300 IKBKG
352 Infantile bilateral striatal necrosis 271930 NUP62
353 Infantile hypophosphatasia 241500 ALPL
354 Infantile neuroaxonal dystrophy 2A 256600 PLA2G6
355 Infantile neuroaxonal dystrophy 2B 610217 PLA2G6
356 Infantile onset spinocerebellar ataxia 271245 C10orf2
357 Interleukin 1 receptor antagonist deﬁciency 612852 IL1RN
358 Isolated CoQ-cytochrome C reductase deﬁciency 124000 BCS1L
359 Isolated growth hormone deﬁciency type III 307200 BTK
360 Isolated thyroid-stimulating hormone deﬁciency 275100 TSHB
361 Isovaleric acidemia 243500 IVD
362 Jeune syndrome 611263 IFT80
363 Johanson-Blizzard syndrome 243800 UBR1
364 Joubert syndrome 4 609583 NPHP1
365 Joubert syndrome 6 610688 TMEM67
366 Joubert syndrome with hepatic defect 216360 RPGRIP1L
367 Joubert syndrome with ocular defect 608629 AHI1
368 Joubert syndrome with oculorenal defect 5 610188 CEP290
369 Junctional epidermolysis bullosa - pyloric atresia 226730 ITGA6
370 Junctional epidermolysis bullosa with piloric atresia 226730 ITGB4
371 Junctional epidermolysis bullosa, Herlitz type (gene LAMA3) 226700 LAMA3
372 Junctional epidermolysis bullosa, Herlitz type (gene LAMB3) 226700 LAMA3
373 Junctional epidermolysis bullosa, Herlitz type (gene LAMC2) 226700 LAMC2
374 Junctional epidermolysis bullosa, non-Herlitz type 226650 ITGB4
375 Junctional epidermolysis bullosa, non-Herlitz type (gene LAMA3) 226650 LAMA3
376 Junctional epidermolysis bullosa, non-Herlitz type (gene LAMB3) 226650 LAMB3
377 Junctional epidermolysis bullosa, non-Herlitz type (gene LAMC2) 226650 LAMC2
378 Juvenile neuronal ceroid lipofuscinosis 3 204200 CLN3
379 Kahrizi syndrome 612713 SRD5A3
380 Kelley-Seegmiller syndrome 300323 HPRT1
381 Kennedy disease 313200 AR
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382 Ketoacidosis due to beta-ketothiolase deﬁciency 203750 ACAT1
383 Krabbe disease 245200 GALC
384 Krabbe disease 611722 PSAP
385 Lacticacidemia due to PDX1 deﬁciency 245349 PDHX
386 Late infantile neuronal ceroid lipofuscinosis 610951 MFSD8
387 Late infantile neuronal ceroid lipofuscinosis 5 256731 CLN5
388 Late infantile neuronal ceroid lipofuscinosis 6 601780 CLN6
389 Late infantile neuronal ceroid lipofuscinosis 8 600143 CLN8
390 Lathosterolosis 607330 SC5DL
391 Leigh syndrome 256000 BCS1L
392 Leigh syndrome 256000 DLD
393 Leigh syndrome 256000 NDUFAF2
394 Leigh syndrome 256000 NDUFS4
395 Leigh syndrome 256000 NDUFS7
396 Leigh syndrome due to cytochrome c oxidase deﬁciency 256000 COX15
397 Leigh syndrome due to mitochondrial complex I deﬁciency 256000 NDUFS3
398 Leigh syndrome due to mitochondrial complex I deﬁciency 256000 NDUFS8
399 Leigh syndrome due to mitochondrial COX4 deﬁciency 256000 COX10
400 Leigh syndrome with nephrotic syndrome 607426 COQ2
401 Leigh syndrome with nephrotic syndrome 614652 PDSS2
402 Leigh syndrome, due to COX deﬁciency 256000 SURF1
403 Leigh syndrome, X-linked 308930 PDHA1
404 Leprechaunism 246200 INSR
405 Lesch-Nyhan syndrome 300322 HPRT1
406 Lethal acantholytic epidermolysis bullosa 609638 DSP
407 Lethal ataxia with deafness and optic atrophy 301835 PRPS1
408 Lethal congenital contractural syndrome 2 607598 ERBB3
409 Lethal congenital contracture syndrome type 1 253310 GLE1
410 Lethal osteosclerotic bone dysplasia 259775 FAM20C
411 Lethal restrictive dermopathy 275210 LMNA
412 Lethal restrictive dermopathy 275210 ZMPSTE24
413 Leukocyte adhesion deﬁciency, type III 612840 FERMT3
414 Leydig cell adenoma, somatic, with precocious puberty 176410 LHCGR
415 Leydig cell hypoplasia with hypergonadotropic hypogonadism 238320 LHCGR
416 Leydig cell hypoplasia with pseudohermaphroditism 238320 LHCGR
417 Lhermitte-Duclos syndrome 158350 PTEN
418 Limb girdle dystrophy with epidermolysis bullosa simplex 613723 PLEC
419 Lissencephaly 3 611603 TUBA1A
420 Lissencephaly syndrome, Norman-Roberts type 257320 RELN
421 Lissencephaly, X-linked 300067 DCX
422 Long chain 3-hydroxyacyl-CoA dehydrogenase deﬁciency 609016 HADH
423 Luteinizing hormone resistance, female 238320 LHCGR
424 Lymphoproliferative syndrome, X-linked, 2 300635 XIAP
425 Macrocephaly/autism syndrome 605309 PTEN
426 Macroglobulinemia, Waldenstrom 153600 MYD88
427 Macular degeneration, age-related, 3 608895 FBLN5
428 Mandibuloacral dysplasia with type A lipodystrophy 248370 LMNA
429 Mandibuloacral dysplasia with type B lipodystrophy 608612 ZMPSTE24
430 Mannosidosis, alpha-, types I and II 248500 MAN2B1
431 Maple syrup urine disease 248600 DLD
432 Maple syrup urine disease (gene BCKDHA) 248600 BCKDHA
433 Maple syrup urine disease (gene BCKDHB) 248600 BCKDHB
434 Marinesco-Sjögren syndrome 248800 SIL1
435 Masa syndrome 303350 L1CAM
436 Meckel syndrome type 1 249000 MKS1
437 Meckel syndrome, type 5 611561 RPGRIP1L
438 Medium chain acyl-CoA dehydrogenase deﬁciency 201450 ACADM
439 Megalencephalic leukoencephalopathy with subcortical cysts 604004 MLC1
440 Menkes disease 309400 ATP7A
441 Mental retardation and microcephaly with pontine and cerebellar hypoplasia 300749 CASK
442 Mental retardation, autosomal recessive 1 249500 PRSS12
443 Mental retardation, autosomal recessive 12 611090 ST3GAL3
444 Mental retardation, autosomal recessive 13 613192 TRAPPC9
445 Mental retardation, autosomal recessive 5 611091 NSUN2
446 Mental retardation, autosomal recessive, 6 611092 GRIK2
447 Mental retardation, with or without nystagmus 300422 CASK
448 Mental retardation, X-linked 300495 NLGN4X
449 Mental retardation, X-linked 19 300844 RPS6KA3
450 Mental retardation, X-linked 21/34 300143 IL1RAPL1
451 Mental retardation, X-linked 30/47 300558 PAK3
452 Mental retardation, X-linked 41 300849 GDI1
453 Mental retardation, X-linked 46 300436 ARHGEF6
454 Mental retardation, X-linked 63 300387 ACSL4
455 Mental retardation, X-linked 72 300271 RAB39B
456 Mental retardation, X-linked 9 309549 FTSJ1
457 Mental retardation, X-linked 90 300850 DLG3
458 Mental retardation, X-linked 93 300659 BRWD3
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459 Mental retardation, X-linked 96 300802 SYP
460 Mental retardation, X-linked 97 300803 ZNF711
461 Mental retardation, X-linked syndromic 16 305400 FGD1
462 Mental retardation, X-linked syndromic 5 304340 AP1S2
463 Mental retardation, X-linked syndromic, Christianson type 300243 SLC9A6
464 Mental retardation, X-linked syndromic, Nascimento-type 300860 UBE2A
465 Mental retardation, X-linked syndromic, Raymond type 300799 ZDHHC9
466 Mental retardation, X-linked syndromic, Turner type 300706 HUWE1
467 Mental retardation, X-linked, FRAXE type 309548 AFF2
468 Mental retardation, X-linked, Snyder-Robinson type 309583 SMS
469 Mental retardation, X-linked, syndromic 14 300676 UPF3B
470 Mental retardation, X-linked, syndromic 15 (Cabezas type) 300354 CUL4B
471 Mental retardation, X-linked, syndromic, Claes-Jensen type 300534 KDM5C
472 Mental retardation, X-linked, with cerebellar hypoplasia and distinctive 300486 OPHN1
facial appearance
473 Mental retardation, X-linked, with isolated growth hormone deﬁciency 300123 SOX3
474 Mental retardation-hypotonic facies syndrome, X-linked 309580 ATRX
475 Metachromatic leukodystrophy 250100 ARSA
476 Metachromatic leukodystrophy 249900 PSAP
477 Metaphyseal chondrodysplasia, Murk Jansen type 156400 PTH1R
478 Metaphyseal dysplasia without hypotrichosis 250460 RMRP
479 Methylmalonic acidemia with homocystinuria, type cblC 277400 MMACHC
480 Methylmalonic acidemia with homocystinuria, type cblD 277410 MMACHC
481 Mevalonic aciduria 610377 MVK
482 Micro syndrome 600118 RAB3GAP1
483 Microphthalmia, syndromic 2 300166 BCOR
484 Mitochondrial complex I deﬁciency 252010 NDUFA1
485 Mitochondrial complex I deﬁciency 252010 NDUFAF2
486 Mitochondrial complex I deﬁciency 252010 NDUFAF4
487 Mitochondrial complex I deﬁciency 252010 NDUFS3
488 Mitochondrial complex I deﬁciency 252010 NDUFS4
489 Mitochondrial complex I deﬁciency 252010 NDUFV1
490 Mitochondrial complex IV deﬁciency 220110 COX10
491 Mitochondrial complex IV deﬁciency 220110 COX6B1
492 Mitochondrial complex IV deﬁciency 220110 FASTKD2
493 Mitochondrial complex IV deﬁciency SCO1
494 Mitochondrial DNA depletion syndrome 1 (MNGIE type) 603041 TYMP
495 Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or 612073 SUCLA2
without methylmalonic aciduria)
496 Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with 612075 RRM2B
renal tubulopathy)
497 Mitochondrial DNA depletion syndrome 8B (MNGIE type) 612075 RRM2B
498 Mitochondrial DNA depletion syndrome, hepatocerebral form due to 251880 DGUOK
DGUOK deﬁciency 3
499 Mitochondrial DNA depletion syndrome, myopathic form 609560 TK2
500 Mitochondrial neurogastrointestinal encephalomyopathy 613662 POLG
501 Mitochondrial respiratory chain complex III deﬁciency 124000 UQCRB
502 Mitochondrial respiratory chain complex III deﬁciency 124000 UQCRQ
503 Mitochondrial trifunctional protein deﬁciency 609015 HADHA
504 Mitochondrial trifunctional protein deﬁciency 609015 HADHB
505 Mohr-Tranebjaerg syndrome 304700 TIMM8A
506 Mowat-Wilson syndrome 235730 ZEB2
507 Mucolipidosis type 2 252500 GNPTAB
508 Mucolipidosis type 3 252600 GNPTAB
509 Mucolipidosis type 4 252650 MCOLN1
510 Mucopolysaccharidosis Ih 607014 IDUA
511 Mucopolysaccharidosis Ih/s 607015 IDUA
512 Mucopolysaccharidosis Is 607016 IDUA
513 Mucopolysaccharidosis type 2 309900 IDS
514 Mucopolysaccharidosis type 3A (Sanﬁlippo syndrome type A) 252900 SGSH
515 Mucopolysaccharidosis type 4B 253010 GLB1
516 Mucopolysaccharidosis type 6 253200 ARSB
517 Mucopolysaccharidosis type 7 253220 GUSB
518 Mucopolysaccharidosis type IIIB (Sanﬁlippo B) 252920 NAGLU
519 MULIBREY nanism 253250 TRIM37
520 Multiple epiphyseal dysplasia type 4 226900 SLC26A2
521 Multiple pterygium syndrome, lethal type 253290 CHRNA1
522 Multiple pterygium syndrome, lethal type 253290 CHRND
523 Multiple pterygium syndrome, lethal type 253290 CHRNG
524 Muscle-eye-brain disease 613153 FKRP
525 Muscle-eye-brain disease 613154 LARGE
526 Myasthenia gravis, neonatal transient 100730 CHRNG
527 Myasthenia, limb-girdle, familial 254300 DOK7
528 Myasthenic syndrome, fast-channel congenital 608930 CHRNA1
529 Myasthenic syndrome, fast-channel congenital 608930 CHRND
530 Myasthenic syndrome, slow-channel congenital 601462 CHRNA1
531 Myasthenic syndrome, slow-channel congenital 601462 CHRND
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532 Myopathy, tubular aggregate, 1 160565 STIM1
533 Myopathy, tubular aggregate, 2 615883 ORAI1
534 Nance-Horan syndrome 302350 NHS
535 Navajo neurohepatopathy 256810 MPV17
536 Nemaline myopathy 2 256030 NEB
537 Neonatal adrenoleukodystrophy (gene PEX12) 266510 PEX12
538 Neonatal adrenoleukodystrophy (gene PEX26) 614873 PEX26
539 Neonatal adrenoleukodystrophy (gene PEX5) 202370 PEX5
540 Nephrolithiasis, type I 310468 CLCN5
541 Nephronophthisis 2, infantile 602088 INVS
542 Nephrotic syndrome, tupe 3 610725 PLCE1
543 Nephrotic syndrome, type 1 256300 NPHS1
544 Nephrotic syndrome, type 2 600995 NPHS2
545 Nephrotic syndrome, type 5, with or without ocular abnormalities 614199 LAMB2
546 Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deﬁciency 250620 HIBCH
547 Neurodegeneration due to cerebral folate transport deﬁciency 613068 FOLR1
548 Neuronal ceroid lipofuscinosis 2 204500 TPP1
549 Neuropathy, congenital hypomyelinating 605253 MPZ
550 Neutropenia, severe congenital 3, autosomal recessive 610738 HAX1
551 Niemann-Pick disease type A 257200 SMPD1
552 Niemann-Pick disease type B 607616 SMPD1
553 Niemann-Pick disease type C1 257220 NPC1
554 Niemann-Pick disease type C2 607625 NPC2
555 Nijmegen breakage syndrome 251260 NBN
556 Norrie disease 310600 NDP
557 ntal retardation, autosomal recessive 7 611093 TUSC3
558 Occipital horn syndrome 304150 ATP7A
559 Oculocerebrorenal syndrome 309000 OCRL
560 Omenn syndrome 603554 DCLRE1C
561 Omenn syndrome (gene RAG1) 603554 RAG1
562 Omenn syndrome (gene RAG2) 603554 RAG2
563 Opitz GBBB syndrome, type I 300000 MID1
564 Ornithine transcarbamylase deﬁciency 311250 OTC
565 Osteogenesis imperfecta type 8 610915 LEPRE1
566 Osteogenesis imperfecta type VII 610682 CRTAP
567 Osteogenesis imperfecta, type I 166200 COL1A1
568 Osteogenesis imperfecta, type II 166210 COL1A1
569 Osteogenesis imperfecta, type III 259420 COL1A1
570 Osteogenesis imperfecta, type IV 166220 COL1A1
571 Osteopetrosis with renal tubular acidosis 259730 CA2
572 Osteopetrosis, autosomal recessive 5 259720 OSTM1
573 Paget disease, juvenile 239000 TNFRSF11B
574 Panhypopituitarism, X-linked 312000 SOX3
575 Pantothenate kinase-associated neurodegeneration 234200 PANK2
576 Partial androgen insensitivity syndrome 312300 AR
577 Pelizaeus-Merzbacher-like due to GJC2 mutation 608804 GJC2
578 Peroxisomal acyl-CoA oxidase deﬁciency 264470 ACOX1
579 Peroxisome biogenesis disorder 11A (Zellweger) 614883 PEX13
580 Peroxisome biogenesis disorder 11B 614885 PEX13
581 Peroxisome biogenesis disorder 6A (Zellweger) 614870 PEX10
582 Peroxisome biogenesis disorder 6B 614871 PEX10
583 Perrault syndrome 233400 HSD17B4
584 Phenylketonuria 261600 PAH
585 Pierson syndrome 609049 LAMB2
586 Pitt-Hopkins syndrome 610954 TCF4
587 Plasminogen deﬁciency type 1 217090 PLG
588 Pontocerebellar hypoplasia type 2A 277470 TSEN54
589 Pontocerebellar hypoplasia type 4 225753 TSEN54
590 Porphyria, congenital erythropoietic 263700 UROS
591 Precocious puberty, male 176410 LHCGR
592 Primary lateral sclerosis, juvenile 606353 ALS2
593 Progressive epilepsy - intellectual deﬁcit, Finnish type 610003 CLN8
594 Properdin deﬁciency, X-linked 312060 CFP
595 Propionic acidemia (gene PCCA) 606054 PCCA
596 Propionic acidemia (gene PCCB) 606054 PCCB
597 CLCN5
598 Proximal spinal muscular atrophy type 1 253300 SMN1
599 Proximal spinal muscular atrophy type 2 253550 SMN1
600 Proximal spinal muscular atrophy type 3 253400 SMN1
601 Proximal spinal muscular atrophy type 4 271150 SMN1
602 Pseudohermaphroditism, male, with gynecomastia 264300 HSD17B3
603 Pseudohypoaldosteronism type 1, autosomal recessive (gene SCNN1A) 264350 SCNN1A
604 Pseudohypoaldosteronism type 1, autosomal recessive (gene SCNN1B) 264350 SCNN1B
605 Pseudohypoaldosteronism type 1, autosomal recessive (gene SCNN1G) 264350 SCNN1G
606 Pseudovaginal perineoscrotal hypospadias 264600 SRD5A2
607 Pycnodysostosis 265800 CTSK
608 Pyogenic bacterial infections, recurrent, due to MYD88 deﬁciency 612260 MYD88
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609 Pyridoxal phosphate-responsive seizures 610090 PNPO
610 Pyruvate carboxylase deﬁciency 266150 PC
611 Pyruvate dehydrogenase phosphatase deﬁciency 608782 PDP1
612 Renal-hepatic-pancreatic dysplasia 208540 NPHP3
613 Renpenning syndrome 309500 PQBP1
614 Rett syndrome, congenital variant 613454 FOXG1
615 Rhizomelic chondrodysplasia punctata type 1 215100 PEX7
616 Rhizomelic chondrodysplasia punctata type 3 600121 AGPS
617 Rigid spine syndrome 602771 SEPN1
618 Roberts syndrome 269000 ESCO2
619 Roussy-Levy syndrome 180800 MPZ
620 Roussy-Levy syndrome 180800 PMP22
621 Sandhoff disease 268800 HEXB
622 Sanﬁlippo syndrome type C 252930 HGSNAT
623 Schneckenbecken dysplasia 269250 SLC35D1
624 Schwartz-Jampel syndrome 255800 HSPG2
625 Seckel syndrome 210600 ATR
626 Senior-Loken syndrome 610189 CEP290
627 Senior-Loken syndrome 606996 NPHP4
628 Senior-Loken syndrome 1 266900 NPHP3
629 Senior-Loken syndrome 5 609254 IQCB1
630 Sensory ataxic neuropathy - dysarthria - ophthalmoparesis 607459 POLG
631 Severe combined immunodeﬁciency due to adenosine deaminase deﬁciency 102700 ADA
632 Severe combined immunodeﬁciency due to complete RAG1/2 deﬁciency 601457 RAG1
633 Severe combined immunodeﬁciency due to complete RAG1/2 deﬁciency 601457 RAG2
634 Severe combined immunodeﬁciency due to DCLRE1C deﬁciency 602450 DCLRE1C
635 Severe combined immunodeﬁciency with microcephaly, growth retardation, and sensitivity to ionizing radiation 611291 NHEJ1
636 Severe combined immunodeﬁciency with sensitivity to ionizing radiation 602450 LIG4
637 Severe generalized recessive dystrophic epidermolysis bullosa 226600 COL7A1
638 Severe neonatal-onset encephalopathy with microcephaly 300673 MECP2
639 Severe T-cell immunodeﬁciency - congenital alopecia - nail dystrophy 601705 FOXN1
640 Short-rib thoracic dysplasia 3 with or without polydactyly 613091 DYNC2H1
641 Shwachman-Diamond syndrome 260400 SBDS
642 Sialidosis, type I 256550 NEU1
643 Sialidosis, type II 256550 NEU1
644 Sickle cell anemia 603903 HBB
645 Simpson-Golabi-Behmel syndrome type 2 300209 OFD1
646 Simpson-Golabi-Behmel syndrome, type 1 312870 GPC3
647 Síndrome de Dursun 612541 G6PC3
648 Sjogren-Larsson syndrome 270200 ALDH3A2
649 Smith-Lemli-Opitz syndrome 270400 DHCR7
650 Sotos syndrome 1 117550 NSD1
651 Spastic paralysis, infantile onset ascending 607225 ALS2
652 Spastic paraplegia type 2, X-linked 312920 PLP1
653 Spinal muscular atrophy with respiratory distress 604320 IGHMBP2
654 Stocco dos Santos X-linked mental retardation syndrome 300434 SHROOM4
655 Stormorken syndrome 185070 STIM1
656 Stüve-Wiedemann syndrome 601559 LIFR
657 Subcortical laminal heteropia, X-linked 300067 DCX
658 Succinyl CoA:3-oxoacid CoA transferase deﬁciency 245050 OXCT1
659 Sudden infant death with dysgenesis of the testes syndrome 608800 TSPYL1
660 Sulﬁte oxidase deﬁciency due to molybdenum cofactor deﬁciency type A (gene MOCS1) 252150 MOCS1
661 Sulﬁte oxidase deﬁciency due to molybdenum cofactor deﬁciency type A (gene MOCS2) 252150 MOCS2
662 Sulfocysteinuria 272300 SUOX
663 Surfactant metabolism dysfunction, pulmonary, 1 265120 SFTPB
664 Surfactant metabolism dysfunction, pulmonary, 2 610913 SFTPC
665 Surfactant metabolism dysfunction, pulmonary, 3 610921 ABCA3
666 Syndromic microphthalmia type 9 601186 STRA6
667 Tay-Sachs disease 272800 HEXA
668 T-B+ severe combined immunodeﬁciency due to gamma chain deﬁciency 300400 IL2RG
669 T-B+ severe combined immunodeﬁciency due to JAK3 deﬁciency 600802 JAK3
670 T-B+ severe combined immunodeﬁciency, X-linked 312863 IL2RG
671 Tetra-amelia, autosomal recessive 273395 WNT3
672 Thrombocythemia 2 601977 MPL
673 Thrombocytopenia, congenital amegakaryocytic 604498 MPL
674 Thrombotic thrombocytopenic purpura, familial 274150 ADAMTS13
675 Tooth agenesis, selective, X-linked 1 313500 EDA
676 Trichothiodystrophy, complementation group A 601675 GTF2H5
677 Tyrosinemia type 1 276700 FAH
678 Tyrosinemia type 2 276600 TAT
679 Tyrosinemia type 3 276710 HPD
680 Ullrich congenital muscular dystrophy 254090 COL6A1
681 Ullrich congenital muscular dystrophy 254090 COL6A2
682 Ullrich congenital muscular dystrophy 254090 COL6A3
683 Unverricht-Lundborg disease 254800 CSTB
684 Usher syndrome type 1 276900 MYO7A
685 Usher syndrome type 1C 276904 USH1C
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Table 1 (Continued)
Disease Name PhenOMIM Gene
686 Usher syndrome type 1G 606943 USH1G
687 Usher syndrome type 2A 276901 USH2A
688 Usher syndrome type 2C 605472 GPR98
689 Usher syndrome type 3A 276902 CLRN1
690 Very long chain acyl-CoA dehydrogenase deﬁciency 201475 ACADVL
691 Vitamin B12-responsive methylmalonic acidemia type cblA 251100 MMAA
692 Vitamin B12-responsive methylmalonic acidemia type cblB 251110 MMAB
693 Vitamin B12-unresponsive methylmalonic acidemia type mut- 251000 MUT
694 Vitamin D-dependent rickets type 2A 277440 VDR
695 Vitamin D-dependent rickets, type I 264700 CYP27B1
696 Waardenburg-Shah syndrome 4A 277580 EDNRB
697 Waardenburg-Shah syndrome 4B 613265 EDN3
698 Walker-Warburg syndrome (gene POMGNT1) 253280 POMGNT1
699 Walker-Warburg syndrome (gene POMT1) 236670 POMT1
700 Walker-Warburg syndrome (gene POMT2) 613150 POMT2
701 Weyers acrodental dysostosis 193530 EVC
702 Wilson disease 277900 ATP7B
703 Wiskott-Aldrich syndrome 301000 WAS
704 Wolcott-Rallison syndrome 226980 EIF2AK3
705 Wrinkly skin syndrome 278250 ATP6V0A2
706 Xeroderma pigmentosum complementation group A 278700 XPA
707 Xeroderma pigmentosum complementation group E 278740 DDB2
708 Xeroderma pigmentosum, group C 278720 XPC
709 Xeroderma pigmentosum/Cockayne syndrome complex complementation group B 610651 ERCC3
710 Xeroderma pigmentosum/Cockayne syndrome complex complementation group D 278730 ERCC2
711 Xeroderma pigmentosum/Cockayne syndrome complex complementation group F 278760 ERCC4
712 Xeroderma pigmentosum/Cockayne syndrome complex complementation group G 278780 ERCC5
713 X-linked agammaglobulinemia 300755 BTK
714 X-linked centronuclear myopathy 310400 MTM1
715 X-linked Charcot-Marie-Tooth disease type 5 311070 PRPS1
716 X-linked creatine transporter deﬁciency 300352 SLC6A8
717 X-linked distal spinal muscular atrophy 300489 ATP7A
718 X-linked hyper-IgM syndrome 308230 CD40LG
719 X-linked intellectual deﬁcit with marfanoid habitus 309520 MED12
720 X-linked lymphoproliferative disease 308240 SH2D1A
721 Odontoonychodermal dysplasia 257980 WNT10A
722 X-linked spinal muscular atrophy type 2 301830 UBA1
723 Zellweger syndrome 1A 214100 PEX1
724 Zellweger syndrome 7A 614872 PEX26
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mutations, and only 29 were found in common [17]. This poor
method uniformity doesn't allow expanded carrier screening be a
recommended test by clinicians.
Lazarin et al. based a classiﬁcation algorithm on four tiers of
severity: profound, severe, moderate and mild. The disease
characteristics chosen were: life span, intellectual disability,
impaired mobility, physical malformations and dysmorphic
features, sensory impairment, immunodeﬁciency/cancer, mental
illness, reduced fertility, available treatment, and expressivity [18].
In this background, variants of uncertain signiﬁcance and non
pathogenic mutations increase the complexity in choosing the
appropriate panel and counselling of patients.
In 2017, the ACOG published a committee opinion about
common genetic conditions for which carrier screening is
recommended: [19]
 Spinal Muscolar Atrophy. This screening should be offered to all
women during preconceptional or prenatal period, and to
patients with a family history of SMA.
 Cystic Fibrosis. This screening should be offered to all women
during preconceptional or prenatal period. Today about two
thousand mutations of the CFTR gene are known and the
complete analysis of the gene is not recommended for routine
screening.
 Hemoglobinopathies. A complete blood count with red blood
cells indices should be offered to all women during and before
pregnancy, also to diagnose their risk of anemia. If a low meancorpuscular volume results, a hemoglobin electophoresis would
also be indicated, especially in some at risk populations: African,
Mediterranean, Middle Easten, Southeast Asia or West Indian
descendants.
 Fragile X Syndrome. This screening should be offered to all women
during preconception and prenatal period, if a family history or
suggestive intellectual disorders occur. If a woman has unexplained
ovarian insufﬁciency or high levels of FSH before the age of 40, an
FMR1 premutation could be present and the screening should be
reccommended. Prenatal diagnosis for fagile X syndrome should be
offered to known carriers of premutation or full mutation.
 Tay-Sachs Disease. This screening should be offered to all women
during preconception and prenatal period, if either member of a
couple belongs to some particular ethnicity, such as Ashkenazi
Jewish, French-Canadian or Cajun, or if there is a suggestive
family history.
 Expanded carrier screening does not replace the above risk-
based screening recommendations
Analytic and clinical validity and utility
Analytic validity of a genetic test deﬁnes its ability to accurately
and reliably measure the genotype of interest. Current commercial
providers use mostly microarray-based genetic tests covering the
most frequent sequence variants in selected genes. Alternatively,
whole genes, and not only selected sequence variants can be
sequenced by next-generation sequencing (NGS) [7].
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predict the associated disorder, including carrier status. It is
currently difﬁcult to assess the clinical validity of screening panels
due to various confounding factors. Many genes are characterized
by numerous variants, not all of them are pathogenic, equally
associated with severe phenotype and not all of them are
necessarily reported in commercially available panels [7].
As to clinical utility, a genetic test is designed to provide clinical
practice with a valid support to improve patient outcomes. In this
case, the aim of preconception carrier screening is to facilitate
reproductive choices and autonomy of couples. Options for future
parents include preimplantation genetic diagnosis, prenatal
diagnosis, using donor sperms or oocytes, adoption, or accepting
the risk of conceiving an affected child [20,21].
Expanded carrier screening may also support prenatal diagno-
sis with early management of genetic disorders [20–22]. For
example screening for ornithine transcarbamylase deﬁciency, a
rare and potentially fatal disoder in a male neonate, could improve
the prognosis [22]. This will also help the parents to better
approach the pregnancy and be ready for psychosocial conse-
quences of having a child with a genetic condition.
Another aspect of the expanded carrier screening is the clinical
implication on the carrier patient. The screening may reveal
genetic conditions that may predispose the carrier to increased
morbidity and mortality. Carriers of ataxia telangiectasia have a
major risk of breast cancer [23] and heterozygosus variants of
glucocerebrosidase gene is linked to Parkinson's disease [24].
Attention should be also paid to the impact of expanded carrier
screening on the health care organizations and burden of cost.
Lynch et al. found that the median time for results disclosure is
about 64 min, ranging from 5 to 229 min with preparation work
being the most time-consuming activity. [25] Carrier screening
requires signiﬁcant increases in genetic counseling time, and new
resources to reduce preparation work or develop other strategies
such as the creation of new models to deliver this type of service
are needed. [25]
Expanded carrier screening and Noninvasive prenatal diagnosis
Sequencing of cell-free DNA in maternal plasma has enabled
deﬁnitive noninvasive prenatal diagnosis for monogenic disorders
and also for pregnancies with unexpected fetal anomalies. The
current standard for testing for Mendelian disorders is gene panels
and that is available for many ultrasound abnormalities like
holoprosencephaly, congenital heart disease, skeletal dysplasia,
and others. Most Mendelian disorders however, are associated
with normal prenatal ultrasound ﬁndings. Future developments
may be toward noninvasive prenatal diagnosis with fetal whole
exome or whole genome sequencing. This has been performed on
limited disorders so farand to generalize it to diagnose the large
number of Mendelian disorders on the expanded carrier screening
panels is premature for now [26]. In fact, this highlights even more
the importance of clear guidelines for expanded carrier screening
panels.
Ethical issues
The introduction of expanded carrier screening raises many
concerns about complex decisions, including preimplantation
genetic diagnosis, prenatal diagnosis, and pregnancy management
and may impact the psychological well-being, perceptions of
health, and feelings of discrimination or stigmatization with social
consequences. Studies have also demonstrated increased distress
levels among carriers [10].Already pregnancy is a very high
emotional state where expanded carrier screening is only one
aspect of many evaluations that the pregnant patient has to dealwith. Therefore, careful appraisal of the advantages and disadvan-
tages for universal screening before conception is necessary.
Obtaining consent has been considered much more challenging as
the carrier screening panels expand [7]. Women may also have a
legitimate interest in not knowing their genetic make up to avoid
serious pshychological consequences.
Conclusion
Expanded carrier screening aims to identify couples who
have an increased risk of having an affected child in order to
facilitate informed reproductive decision making. New genetic
testing technologies enable the expansion of screening to
multiple conditions including those with very low carrier
frequency, and those with mild or incompletely penetrant
phenotypes. Priority should be given to carrier screening panels
that include a comprehensive set of severe childhood-onset
disorders. Panels should have high clinical validity and clinical
utility. Psychosocial support and genetic couseling should be
available prior to screening and for the return of positive
results. Systems are needed to reduce the risk of misinter-
preting results. Finally, attention should be paid on the impact
of expanded carrier screening on health care organization and
burden of cost.
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